『Daily, Sun 8 Nov: When a better blood marker doesn't help patients』のカバーアート

Daily, Sun 8 Nov: When a better blood marker doesn't help patients

Daily, Sun 8 Nov: When a better blood marker doesn't help patients

無料で聴く

ポッドキャストの詳細を見る
概要

This episode covers Akeso's ivonescimab priority review in China, new HORIZON and ZEUS cardiovascular trial details, and earlier Asian research on Kylo-11 and tocilizumab. Plus Allist and Zhifei development steps, AstraZeneca's China infrastructure, vascular devices and Asian egg-bioreactor services.

Full transcript and all sources for this episode

Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Neither Basil nor Ning holds investments in any company mentioned.

Chapters
0:00 Intro and AI-voice disclosure
1:00 Akeso: review versus approval
3:06 China: trial steps and infrastructure
4:41 HORIZON, ZEUS and Eastern context
7:29 Beyond: vascular-device investment
9:07 Beyond: egg-bioreactor tools
11:28 What to watch and Monday sign-off

Key sources: Akeso: priority review · AHA: HORIZON · AHA: ZEUS (all sources on the episode page)

Weekly LinkedIn newsletter

Also listen on: Apple Podcasts · Amazon Music · YouTube

Tell us what you want us to read next, or what we got wrong, in the comments on the weekly LinkedIn newsletter.

adbl_web_anon_alc_button_suppression_t1
まだレビューはありません